Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EPS (Weighted Average and Diluted) (2022 - 2025)

Historic EPS (Weighted Average and Diluted) for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$0.32.

  • Atara Biotherapeutics' EPS (Weighted Average and Diluted) rose 8907.85% to -$0.32 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3, marking a year-over-year increase of 11289.06%. This contributed to the annual value of -$11.41 for FY2024, which is 8250.45% up from last year.
  • According to the latest figures from Q3 2025, Atara Biotherapeutics' EPS (Weighted Average and Diluted) is -$0.32, which was up 8907.85% from $0.19 recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' EPS (Weighted Average and Diluted) registered a high of $3.5 during Q1 2025, and its lowest value of -$16.91 during Q2 2023.
  • Moreover, its 4-year median value for EPS (Weighted Average and Diluted) was -$0.87 (2022), whereas its average is -$4.01.
  • In the last 5 years, Atara Biotherapeutics' EPS (Weighted Average and Diluted) crashed by 949444.44% in 2023 and then surged by 16199.83% in 2025.
  • Over the past 4 years, Atara Biotherapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.73 in 2022, then crashed by 1806.85% to -$13.92 in 2023, then skyrocketed by 87.82% to -$1.7 in 2024, then surged by 81.12% to -$0.32 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.32 for Q3 2025, versus $0.19 for Q2 2025 and $3.5 for Q1 2025.